Literature DB >> 29448840

Inverse association between serum albumin and future risk of venous thromboembolism: interrelationship with high sensitivity C-reactive protein.

Setor K Kunutsor1, Samuel Seidu2,3, Devvrat T Katechia4, Jari A Laukkanen5,6.   

Abstract

PURPOSE: We aimed to assess the prospective association of serum albumin with venous thromboembolism (VTE) risk and evaluate if the association is independent of or modified by inflammation, as measured by high sensitivity C-reactive protein (hsCRP).
DESIGN: We analysed data of 2176 men aged 42-61 years free from VTE in the Kuopio Ischemic Heart Disease study, with serum albumin concentrations measured at baseline using Coulter's bromocresol purple colorimetric assays. Hazard ratios (HRs) (95% confidence intervals [CI]) were calculated for VTE.
RESULTS: There were 109 validated cases of VTE recorded during a median follow-up of 24.9 years. The risk of VTE increased linearly below a serum albumin concentration of ∼48 g/l. In Cox regression analysis adjusted for established risk factors and other potential confounders, the HR (95% CI) for VTE per 1 standard deviation lower serum albumin was 1.23 (1.02-1.47). The association remained persistent on further adjustment for hsCRP 1.22 (1.01-1.46). Furthermore, the association was not modified by hsCRP and persisted on exclusion of men with elevated hsCRP levels.
CONCLUSIONS: In middle-aged Caucasian men, low serum albumin is associated with an increased risk of VTE, consistent with a linear dose-response relationship. The association is independent of and not modified by inflammation. Key messages   • Serum albumin may be associated with future risk of venous thromboembolism (VTE); however, the shape, nature, magnitude and consistency of the association is uncertain.   • In a population-based prospective cohort study, low serum albumin was associated with an increased risk of VTE in a linear dose-response manner and this association was independent of and not modified by inflammation.   • Serum albumin concentrations may play a role in the development of VTE.

Entities:  

Keywords:  Serum albumin; cohort study; inflammation; venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 29448840     DOI: 10.1080/07853890.2018.1441537

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  6 in total

1.  Serum Albumin and Future Risk of Hip, Humeral, and Wrist Fractures in Caucasian Men: New Findings from a Prospective Cohort Study.

Authors:  Setor K Kunutsor; Ari Voutilainen; Michael R Whitehouse; Samuel Seidu; Jussi Kauhanen; Ashley W Blom; Jari A Laukkanen
Journal:  Med Princ Pract       Date:  2019-03-21       Impact factor: 1.927

2.  Circulating Serum Copper Is Associated with Atherosclerotic Cardiovascular Disease, but Not Venous Thromboembolism: A Prospective Cohort Study.

Authors:  Setor K Kunutsor; Richard S Dey; Jari A Laukkanen
Journal:  Pulse (Basel)       Date:  2021-11-19

3.  Serum Albumin Is Associated With Higher Inflammation and Carotid Atherosclerosis in Treated Human Immunodeficiency Virus Infection.

Authors:  Sahera Dirajlal-Fargo; Manjusha Kulkarni; Emily Bowman; Lingpeng Shan; Abdus Sattar; Nicholas Funderburg; Grace A McComsey
Journal:  Open Forum Infect Dis       Date:  2018-11-17       Impact factor: 3.835

4.  The Prognostic Nutritional Index May Predict Left Atrial Appendage Thrombus or Dense Spontaneous Echo Contrast in Patients With Atrial Fibrillation.

Authors:  Zhao Wang; Binhao Wang; Guohua Fu; Bin He; Huimin Chu; Shengmin Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-29

5.  No evidence of a prospective relationship between serum zinc and venous thromboembolism in Caucasian men: a cohort study.

Authors:  Setor K Kunutsor; Sae Young Jae; Jari A Laukkanen
Journal:  Biometals       Date:  2022-06-10       Impact factor: 3.378

6.  Circulating Serum Magnesium and the Risk of Venous Thromboembolism in Men: A Long-Term Prospective Cohort Study.

Authors:  Setor K Kunutsor; Jari A Laukkanen
Journal:  Pulse (Basel)       Date:  2021-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.